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Introduction: Pancreatic ductal adenocarcinoma (PDAC) remains a major cause of 
cancer-related death. Since significant upregulation of αvβ6 integrin has been reported in PDAC, 
this integrin is a promising target for PDAC detection. In this study, we aimed to develop a 
radioiodinated probe for the imaging of αvβ6 integrin-positive PDAC with single-photon 
emission computed tomography (SPECT). 
Methods: Four peptide probes were synthesized and screened by competitive and saturation 
binding assays using 2 PDAC cell lines (AsPC-1, αvβ6 integrin-positive; MIA PaCa-2, αvβ6 
integrin-negative). The probe showing the best affinity was used to study the biodistribution assay, 
an in vivo blocking study, and SPECT imaging using tumor bearing mice. Autoradiography and 
immunohistochemical analysis were also performed. 
Results: Among the 4 probes examined in this study, 125I-IFMDV2 showed the highest affinity 
for αvβ6 integrin expressed in AsPC-1 cells and no affinity for MIA PaCa-2 cells. The 
accumulation of 125I-IFMDV2 in the AsPC-1 xenograft was 3−5 times greater than that in the 
MIA PaCa-2 xenograft, consistent with the expression of αvβ6 integrin in each xenograft, and 
confirmed by immunohistochemistry. Pretreatment with excess amounts of A20FMDV2 
significantly blocked the accumulation of 125I-IFMDV2 in the AsPC-1 xenograft, but not in the 
MIA PaCa-2 xenograft. Furthermore, 123I-IFMDV2 enabled clear visualization of the AsPC-1 
xenograft. 









Pancreatic ductal adenocarcinoma (PDAC) remains a major cause of cancer-related death, 
despite advances in surgical and medical care [1]. The majority of the patients present with locally 
advanced or metastatic disease and die within 6–12 months. Unfortunately, most cases of PDAC 
are diagnosed at an advanced stage, when the disease has spread and is not amenable to surgical 
intervention, leading to dismal survival rates [2]. This can be explained by the fact that early 
PDAC is minimally symptomatic and lacks specific clinical features. Thus, development of a 
method for PDAC detection at an early stage is desirable.  
The αvβ6 integrin is an epithelial-specific integrin and usually not detectable on 
non-pathologic tissues. It is significantly upregulated by many cancers and is identified as a 
prognostic marker [3,4]. The expression of αvβ6 integrin was strongest in PDAC among other 
gastrointestinal adenocarcinomas and significant upregulation of αvβ6 integrin has been linked to 
malignancy of PDAC [5]. These data suggest that αvβ6 integrin is a promising target for not only 
detection but also prognosis of PDAC. 
The αvβ6 integrin binds to the arginine-glycine-aspartate (RGD) motif in its ligand, 
which includes fibronectin and tenascin. Furthermore, recent studies confirmed the importance of 
the DLXXL region in αvβ6-dependent binding, where L indicates leucine and X indicates the 
location of a nonspecific amino acid [6]. Several peptides containing such motif (A20FMDV2 [7], 
TP H2009.1 [8], Bpep [9], and Peptide 29 [10]) have been identified by phage display screening 
to bind specifically to αvβ6 integrin. However, the binding affinity of each peptide was not 
evaluated quantitatively except for A20FMDV2, which showed nM-order affinity to αvβ6 integrin 
and has already been labeled with 18F and 64Cu for positron emission tomography (PET) imaging 
6 
[7,11,12] and with 111In for single-photon emission computed tomography (SPECT) imaging [13]. 
To our knowledge, imaging probes based on the other 3 peptides have not been developed. 
Although an 111In-labeled A20FMDV2 probe for SPECT imaging has already been 
developed, no radioiodinated peptide probes targeting αvβ6 integrin have been reported so far. In 
terms of half-life, the specific activity of 123I is higher than that of 111In. A probe with higher 
specific activity can produce an image with enhanced contrast. Thus, we aimed to develop a 
123I-labeled peptide probe to visualize αvβ6-integrin-positive PDAC by SPECT. Since the 
introduction of 18F- or 64Cu-labeling sites to the N-terminus of A20FMDV2 did not affect the 
binding to αvβ6 integrin, glycylcysteine was introduced at the N-terminus of each peptide to label 
site-specifically using N-(m-[123/125I]iodophenyl)maleimide (IPM). The binding affinity of the 
IPM-conjugated peptides obtained was measured, and then the peptide showing the highest 
affinity was utilized for the in vivo evaluation as an αvβ6 integrin imaging probe. 
 
2. Materials and Methods 
2.1. Peptide synthesis 
The 9-fluorenylmethyloxycarbonyl (Fmoc)-protected amino acids and 
Fmoc-NH-SAL-PEG Resin were purchased from Watanabe Chemical Industries, Ltd. (Hiroshima, 
Japan). A20FMDV2 and GC-A20FMDV2 were automatically synthesized by Fmoc solid-phase 
peptide synthesis and the conjugation of the peptides and IPM was performed according to a 
previously described method [14]. Other IPM-conjugated peptides (Table 1) were purchased from 




Na[125I]I was purchased from MP Biomedicals, Inc. (Santa Ana, CA). NH4[123I]I was 
kindly supplied from Nihon Medi-Physics Co., Ltd. (Tokyo, Japan). Radiolabeling of the peptides 
was performed according to a procedure described previously [14]. The radiochemical yields of 
123I-IFMDV2 and 125I-IFMDV2 were approximately 30% and 60%, respectively. The 
radiochemical purity of both probes was >99% (Supplementary Fig. 1). Both probes were 
obtained in no-carrier-added conditions. 
 
2.3. Cell Culture 
AsPC-1 human pancreatic carcinoma cells were obtained from the European Collection 
of Cell Cultures (ECACC) and maintained in Roswell Park Memorial Institute medium (RPMI; 
Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) supplemented with 10% heat-inactivated fetal 
bovine serum (FBS). MIA PaCa-2 human pancreatic carcinoma cells were also obtained from 
ECACC and maintained in Dulbecco’s modified Eagle’s medium (Nissui Pharmaceutical) 
supplemented with 10% heat-inactivated FBS. The culture media were supplemented with 
penicillin (100 units/mL) and streptomycin (100 μg/mL). Cells were incubated at 37°C in a 
well-humidified incubator with 5% CO2 and 95% air. 
 
2.4. Competitive binding assay 
AsPC-1 cells were grown to confluency in 24-well plates and washed with PBS. 
125I-IFMDV2 (50 µL, no-carrier-added conditions) was incubated with a competitor peptide 
(varying from 1 pM to 10 µM) in a 24-well plate together with 400 µL of RPMI. The plates were 
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incubated at 37°C for 90 min, after which the wells were washed twice with 1 mL of ice-cold 
RPMI, and then the cells were lysed with 1 mL of 0.2 M NaOH for 15 min. The radioactivity of 
the lysates was measured on a gamma counter (Cobra 2; Packard Instruments), and the protein 
concentration of the lysates was determined by BCA protein assay. The 50% inhibiting 
concentration (IC50) values were calculated by nonlinear regression analysis using GraphPad 
Prism 5 (GraphPad Software, Inc., San Diego, CA). Each experiment was carried out with 
triplicate wells and repeated 3 times. 
 
2.5. Saturation binding assay 
AsPC-1 and MIA PaCa-2 cells were grown to confluency in 24-well plates and washed 
with PBS. Various concentrations of 125I-IFMDV2 (0.25–100 nM; specific activity, 8.14 
GBq/μmol) in RPMI were added to each well. To determine non-specific binding, 
non-radiolabelled A20FMDV2 (10 µM) was also added to some wells. The incubation, wash, and 
measurement of radioactivity and protein concentration were performed in the same way as 
described in the Competitive binding assay section. The specific binding of 125I-IFMDV2 was 
calculated by subtracting the non-specific binding from the total cell-bound radioactivity. Using 
non-linear regression analysis with GraphPad Prism, the equilibrium dissociation constant (Kd) 
values were determined. Each experiment was carried out with triplicate wells and repeated 3 
times. 
 
2.6. Animal Model 
Animal studies were conducted in accordance with our institutional guidelines, and the 
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experimental procedures were approved by the Kyoto University Animal Care Committee. Male 
severe combined immunodeficiency mice (C.B-17/Icr-scid/scid Jcl) at 5 weeks of age were 
purchased from CLEA Japan, Inc. and kept at a constant ambient temperature with a 12-h 
light/dark cycle and free access to food and water. Models of AsPC-1 and MIA PaCa-2 tumors 
were prepared using subcutaneous injections of AsPC-1 cells (1.5 × 106 cells in 100 μL PBS; right 
shoulder) and MIA PaCa-2 cells (2 × 106 cells in 100 μL PBS; left shoulder). Approximately 1 
month after the implantation, the mice were subjected to a tracer study. The average diameter of 
the tumors was 10 mm. 
 
2.7. Biodistribution 
125I-IFMDV2 (37 kBq) was injected intravenously into tumor-bearing mice (n = 4); the 
mice were killed at 10, 60, 120, and 240 min after 125I-IFMDV2 administration. Whole organs 
were immediately harvested and weighed, and their radioactivity was measured. The results were 
expressed as the percentage injected dose per gram (%ID/g) except for the neck (%ID). 
To confirm that the probe was taken up specifically by αvβ6 integrin, 125I-IFMDV2 
(0.017 nmol/37 kBq; no-carrier-added conditions) was injected with or without an excess amount 
of non-radiolabelled A20FMDV2 (20 nmol) into tumor-bearing mice (n = 6−7). Biodistribution 
was determined 1 h post-injection according to the same method described above. 
 
2.8. SPECT/X-ray computed tomography (CT) imaging 
An FX3300 pre-clinical imaging system equipped with a FLEX Triumph multi-modality 
pre-clinical imaging platform (Gamma Medica, Inc., Northridge, CA) was used to acquire and 
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process the SPECT and CT data. Mice bearing AsPC-1 xenografts were given intravenous 
injections ranging from 28 to 45 MBq of 123I-IFMDV2 in a volume of 120 µL (n = 3). At 40 min 
after administration, the mice were anesthetized with 1.5% isoflurane, and tomographic spiral 
SPECT scans were performed for 40 min using a 4-head detector camera. Immediately after 
SPECT acquisition, CT acquisition of the anesthetized mice was performed. The acquisition and 
reconstruction of images were performed according to a previously described method [15]. After 
CT acquisition, the mice were euthanized by exsanguination. Blood was collected and tumors 
were harvested and weighed immediately, and their radioactivity was measured. 
 
2.9. Autoradiography and histological analysis 
The tumors were removed and frozen in hexane (−80°C) at 1 h after a 123I-IFMDV2 
(10.5 MBq) injection. The frozen tumor samples were sliced into 20-µm–thick sections and 
adjacent 4-µm–thick sections with a cryomicrotome (CM1900 Cryostat; Leica Microsystems, 
Wetzlar, Germany). Autoradiograms were obtained and analyzed according to the previously 
described method [16].  
 The serial 4-µm–thick sections were subjected to hematoxylin–eosin (HE) staining and 
detection with an anti-αvβ6 mouse mAb (Millipore). For specific detection of the immune 
reactions, we employed a MOM kit (Vector Laboratories Inc., Burlingame, CA), and then 
incubated with 10 µg/mL anti-αvβ6 mAb at 4°C for 10 h followed by a secondary antibody, Alexa 
Fluor 488-labelled anti-mouse IgG (Life Technologies, Carlsbad, CA) for 1 h at room temperature. 
Hoechst33342 (Life Technologies) was used for nuclear staining. The slides were mounted in 
Prolong Gold antifade reagent (Life Technologies), and photo data were acquired using a TCS 
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SP5II confocal microscope (Leica Microsystems). 
 
2.10. Statistical analyses 
The data are expressed as mean ± SD. A Mann–Whitney U test was performed to 





3.1. Competitive binding assay 
The affinity-related IC50 values are shown in Table 2. A20FMDV2 showed the highest 
affinity for AsPC-1 cells. The affinity of IFMDV2 was slightly lower than that of A20FMDV2 but 
still on the order of 10 nM. On the other hand, other probes had more than 10 times less affinity 
than A20FMDV2. The αvβ3 integrin-targeting peptide (cyclo-RGDfK; ABX GmbH, Radeberg, 
Germany) did not inhibit the binding of 125I-IFMDV2 to AsPC-1 cells. 
 
3.2. Saturation binding assay 
The specific binding data and saturation curves are shown in Fig. 1A. The binding of 
125I-IFMDV2 to AcPC-1 cells was increased in a dose-dependent manner and the Kd value was 
determined to be 6.6 ± 2.0 nM. In contrast, 125I-IFMDV2 showed no affinity for MIA PaCa-2 cells. 
Western blot analysis confirmed remarkable αvβ6 integrin expression in AsPC-1 cells while no 
obvious αvβ6 integrin expression was observed in MIA PaCa-2 cells (Fig. 1B). 
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3.3. Biodistribution studies 
A high level of radioactivity accumulated in the kidneys and liver 10 min after injection, 
but it reduced rapidly. In contrast, the level of radioactivity in the intestine increased sequentially, 
which suggests that part of the administered 125I-IFMDV2 is excreted in bile. The uptake of 
125I-IFMDV2 in the AsPC-1 xenograft was more than 3 times higher than that in the MIA PaCa-2 
xenograft, and the AsPC-1-to-blood and AsPC-1-to-muscle ratios were greater than 1 for all time 
points examined (Table 3). Pretreatment with excess A20FMDV2 induced a 62% decrease in 
125I-IFMDV2 accumulation in the AsPC-1 xenograft. On the other hand, the radioactivity in blood 
and MIA PaCa-2 xenograft was not affected significantly (Fig. 2).  
 
3.4. SPECT/CT imaging 
The AsPC-1 xenograft was clearly visualized 1 h after the 123I-IFMDV2 injection (Fig. 3). 
The radioactivity accumulated in the AsPC-1 xenografts at the end of the SPECT acquisition, i.e., 
80 min after injection of 123I-IFMDV2, was 0.74 ± 0.43 %ID/g. The tumor-to-blood ratio was 
1.73 ± 0.56. 
 
3.5. Autoradiography and histological analysis 
Autoradiographic images of 123I-IFMDV2 are shown in Fig. 4 (A: AsPC-1, B: MIA 
PaCa-2) and both images are at the same scale. HE staining revealed that there was 1 large tumor 
cell nest in Fig. 4C (AsPC-1) and there were large and small tumor cell nests in Fig. 4D (MIA 
PaCa-2). 123I-IFMDV2 strongly accumulated in the AsPC-1 xenograft, but rarely accumulated in 
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the MIA PaCa-2 xenograft. The arrowhead indicates a necrotic area in the MIA PaCa-2 sample, 
and radioactivity was retained in the area. On immunohistochemistry, αvβ6 integrin was markedly 




The purpose of the present study was to develop a radioiodinated peptide probe targeting 
αvβ6 integrin. After in vitro screening, we found that 125I-IFMDV2 had a high affinity and 
selectivity for αvβ6 integrin. The in vivo accumulation of 125I-IFMDV2 in αvβ6 integrin-positive 
tumors was greater than that in αvβ6 integrin-negative tumors. The accumulation was 
significantly blocked by pretreatment with an excess amount of A20FMDV2, indicating the 
specific binding of 125I-IFMDV2 to αvβ6 integrin in vivo. Furthermore, 123I-IFMDV2 could 
clearly visualize the αvβ6 integrin-positive tumor. These findings suggest that 123I-IFMDV2 is a 
potential probe for SPECT imaging of αvβ6 integrin-positive tumors.  
Although 123I-IFMDV2 is the first radioiodinated probe targeting αvβ6 integrin, several 
probes containing the same amino acid sequence, i.e., A20FMDV2, and labeled with other 
radionuclides have already been developed. The accumulation of 123I-IFMDV2 (1.31%ID/g at 1 
h) in tumors was superior to that of 18F-A20FMDV2 (0.66%ID/g at 1 h) [7], but inferior to that of 
111In-DTPA-A20FMDV2 (2.1%ID/g at 1 h) [13]. One reason for this may be the difference in 
binding affinity to αvβ6 integrin. Although the Kd value of 123I-IFMDV2 (6.6 nM) was 
sufficiently high for successful SPECT imaging, it was 4-fold lower than that of 
111In-DTPA-A20FMDV2 (1.7 nM) [13]. Another reason may be the difference in intracellular 
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retention of the probes. Duncan and Welch reported that 111In-DTPA-polypeptides were delivered 
to the lysosome after internalization, following which they were retained within the lysosome and 
were only slowly released from the cell [17]. In fact, a comparison of the biodistribution between 
111In-DTPA-antibody and 125I-antibody revealed that the retention of 111In in the tumor was 
significantly higher than that of 125I [18]. 
The drawback of the 18F-A20FMDV2 probe was low uptake and poor retention in the 
tumor (0.66%ID/g at 1 h and 0.06%ID/g at 4 h) [7]. However, the authors succeeded in improving 
the biodistribution of the probe by conjugating polyethylene glycol (PEG) with A20FMDV2. 
Radioactive probe accumulation in αvβ6 integrin-positive tumor was approximately 
1.5−2.0%ID/g 1 h after injection of 18F-PEG28-A20FMDV2 and 18F-(PEG28)2-A20FMDV2, and 
continued until 4 h after the injection [19]. The accumulation of the probes in tumors was greater 
than that of 123I-IFMDV2. Although the detailed mechanism of increased accumulation and 
retention in tumors has not yet been elucidated, it could be attributed to increased probe stability 
in plasma [20]. 123I-IFMDV2 was also rapidly cleared from the tumor (1.31%ID/g at 1 h and 
0.24%ID/g at 4 h) and was instable in plasma. Thus, PEGylation would be effective to increase 
accumulation and retention of 123I-IFMDV2 in the tumor. 
Integrins are transmembrane receptors that connect the extracellular matrix to the 
cytoskeleton, and influence the regulation of cell survival, proliferation, gene transcription, and 
migration. To date, 18 different α and 8 different β subunits have been identified, forming 24 
different integrin receptors. Among them, αvβ3 integrin has been most extensively studied, and 
many probes targeting αvβ3 integrin have been developed [21,22,23]. Yoshimoto et al. reported 
the usefulness of SPECT imaging with 111In-labeled c(RGDfK), an imaging probe of αvβ3 
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integrin, for the early detection of pancreatic cancer in a hamster model of pancreatic 
carcinogenesis [24]. Therefore, not only αvβ6 integrin but also αvβ3 integrin are potential targets 
for the detection of PDAC. However, the immunohistochemical analyses using human PDAC 
samples revealed that αvβ3 integrin was expressed in 29 of 50 samples [25], whereas αvβ6 
integrin was expressed in 33 of 34 samples [5]. Thus, probes targeting αvβ6 integrin may detect 
PDAC with greater sensitivity than those targeting αvβ3 integrin. Furthermore, microarray 
analysis revealed that not the β3- but the β6-integrin gene was upregulated in PDAC samples with 
a poor outcome. Interestingly, the upregulation of the β6-integrin gene was not observed in those 
with a good outcome [26]. These findings suggest that probes targeting αvβ6 integrin can give 
information about the prognosis of PDAC. 
Phage display analysis identified the DLXXL sequence as a key moiety responsible for 
αvβ6 specificity while having only minimal interactions with αvβ3, αvβ5, and αIIbβ3 [27]. In fact, 
the binding of 125I-IFMDV2 to αvβ6 integrin expressed in AsPC-1 cells was not inhibited by a 
RGD peptide lacking a DLXXL sequence (cyclo-[RGDfK]). This finding indicates high 
selectivity of 125I-IFMDV2 to αvβ6 integrin. Among the peptides containing the DLXXL 
sequence, IFMDV2 showed the highest affinity for AsPC-1 cells. We preliminarily evaluated the 
affinity of IPM-conjugated TP-H2009.1 and Bpep at the C-terminus, but found the affinity of 
those probes was lower than that of IFMDV2 (data not shown). However, these findings do not 
necessarily deny the possibility of using the sequences examined in this study (except for 
A20FMDV2) as a basic scaffold for an αvβ6 integrin targeting probe. In the present study, we 
screened the probes with a single prosthetic group (IPM) and a fixed length of spacer (glycine). 
Other prosthetic groups for radioiodination, such as N-succinimidyl-3-iodobenzoate [28], have 
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been reported. The use of different prosthetic groups and/or different kinds and lengths of spacers 





123/125I-IFMDV2 showed high affinity and specificity for αvβ6 integrin both in vitro and 
in vivo. The αvβ6-integrin-positive pancreatic cancer was clearly visualized and thus, 
123I-IFMDV2 is a potential SPECT probe for the imaging of αvβ6 integrin in PDAC. It could 
bring valuable information not only for the detection of αvβ6-integrin-positive tumors but also for 
the evaluation of the efficacy of αvβ6-integrin targeted therapy. 
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Table 1. Probes evaluated in this study 
Name Amino acid sequence 
IPM-A20FMDV2 (IFMDV2) C(IPM)GNAVPNLRGDLQVLAQKVART 
IPM-TP H2009.1 C(IPM)GRGDLATLRQLAQEDGVVGVR 
IPM-Peptide29 Cyclo-(CRGDLASLC)GGGGGGC(IPM) 
IPM-Bpep C(IPM)GRTDLDSLRTYTL 
Underlines designate RG(T)DLXXL sequences. 
IPM, N-(m-iodophenyl)maleimide. 
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Table 2. IC50 values of the probes  
Name IC50 (nM) 
A20FMDV2 17 ± 2 
IFMDV2 40 ± 25 
IPM-TP H2009.1 420 ± 220 
IPM-Peptide29 205 ± 134 
IPM-Bpep >10000 
Cyclo-(RDGfK) >10000 
Values are represented as the mean ± S.D., n = 3. 
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Table 3. Biodistribution of 125I-IFMDV2 
 Time after injection (min) 
Organ 10 60 120 240 
Blood 1.34 ± 0.10 0.44 ± 0.06 0.16 ± 0.03 0.10 ± 0.04 
AsPC-1 xenograft 2.60 ± 0.68 1.31 ± 0.10 0.43 ± 0.13 0.24 ± 0.11 
MIA PaCa-2 xenograft 0.83 ± 0.09 0.25 ± 0.04 0.13 ± 0.13 0.06 ± 0.06 
Pancreas 2.48 ± 0.11 0.40 ± 0.10 0.19 ± 0.21 0.08 ± 0.10 
Liver 7.80 ± 0.65 7.55 ± 0.63 1.57 ± 0.53 0.57 ± 0.30 
Intestine 7.86 ± 1.59 11.99 ± 2.39 15.51 ± 1.82 11.61 ± 2.94 
Kidneys 69.61 ± 3.31 11.10 ± 1.06 2.17 ± 0.47 1.59 ± 0.76 
Muscle 1.58 ± 0.38 0.85 ± 0.08 0.38 ± 0.16 0.14 ± 0.12 
Neck 0.08 ± 0.03 0.05 ± 0.02 0.04 ± 0.01 0.07 ± 0.04 
AsPC-1/Blood ratio 1.96 ± 0.60 2.99 ± 0.54 2.86 ± 1.21 2.48 ± 0.75 
AsPC-1/Muscle ratio 1.75 ± 0.55 1.55 ± 0.19 1.35 ± 0.67 2.03 ± 0.53 
Organ uptake values are expressed as %ID/g of tissue, except in the case of the neck (%ID), and 
AsPC-1/Blood and AsPC-1/Muscle ratios.  






(A) Saturation binding curves of 125I-IFMDV2 in AsPC-1 and MIA PaCa-2 cells. Specific binding 
data calculated by subtracting the non-specific binding from the total binding are shown.  
(B) Western blot analysis of β6 integrin expression in AsPC-1 (Lane A) and MIA PaCa-2 (Lane 







Effects of A20FMDV2 pretreatment on 125I-IFMDV2 accumulation in blood, AsPC-1, and MIA 
PaCa-2 xenografts. Each column represents an average of 6–7 animals and each error bar 







A representative SPECT/CT image of an AsPC-1-implanted mouse 1 h after injection with 







Representative images of 123I-IFMDV2 autoradiograms (A, B), hematoxylin–eosin staining (C, D), 
and αvβ6 integrin immunostaining (E, F). Tumor sections in A, C, and E were obtained from an 
AsPC-1 xenograft, and those in B, D, and F were obtained from a MIA PaCa-2 xenograft. The 
arrows indicate tumor cell nests and the arrowhead indicates a necrotic area. The squares indicate 
the areas that correspond to panels E and F. αvβ6 integrin was immunostained in green and nuclei 




Materials and Methods 
Characterization of the peptides 
The peptides were characterized by analytical high-performance liquid chromatography 
(HPLC) (5C18-AR-II column; 4.6 × 150 mm; Nacalai Tesque, Inc., Kyoto, Japan) and 
matrix-assisted laser desorption/ionization mass spectrometry (AXIMA-CFR Plus; Shimadzu 
Corporation, Kyoto, Japan) before use. The mobile phase was a linear gradient with solvent A 
(0.1% TFA in water) and solvent B (0.1% TFA in acetonitrile) starting at 20% solvent B and 
increasing to 50% over 30 min. The flow rate was 1 mL/min and the wavelength of ultraviolet 
detection was 220 nm. 
 
Serum stability determination 
The stability of 125I-IFMDV2 was tested in mouse serum (0.3 mL). After incubation for 
10, 60, and 120 min at 37°C, 50 μL of the sample was removed and mixed with 100 μL of 
acetonitrile. The mixture was centrifuged, and the supernatant was analyzed by HPLC under 




Whole protein was extracted from AsPC-1 and MIA PaCa-2 cells using Passive Lysis 
Buffer (Promega Corporation, Madison, WI) with 1% protease inhibitor. After the protein 
concentration of the lysates was measured using a BCA protein assay kit (Thermo Scientific, 
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Rockford, IL), 20 μg of protein was separated by sodium dodecylsulfate-polyacrylamide gel 
electrophoresis (e-PAGEL E-T/R/D520L; ATTO Corporation, Tokyo, Japan) under non-reducing 
conditions. Proteins were transferred to a nitrocellulose membrane (Millipore Corporation, 
Billerica, MA). After blocking with Blocking One (Nacalai Tesque, Inc.) at 4°C, membranes were 
probed with anti-β6 mouse monoclonal antibody (mAb) (Millipore). Membranes were washed 3 
times for 10 min with phosphate-buffered saline (PBS) and 0.1% Tween-20 and incubated with a 
secondary antibody (horseradish peroxidase-conjugated goat anti-mouse IgG3 antibody [Santa 
Cruz Biotechnology, Inc., Santa Cruz, CA]) for 45 min at room temperature, and the washing step 
was repeated. Protein bands were visualized using an ECL Plus kit (GE Healthcare UK Ltd., 
Buckinghamshire, UK) with a gel imaging system (ChemiDoc XRS; BIO-RAD Laboratories, 
Hercules, CA). Immunoblotting for β-actin was used as a protein loading control. 
 
Results 
Characterization of the peptides 
A20FMDV2: calculated for C93H164N32O27 (M+H+); m/z, 2162.52; found, 2162.80. 
GC-A20FMDV2: calculated for C98H172N34O29S (M+H+); m/z, 2322.28; found, 2322.30.  
IFMDV2: calculated for C108H178IN35O31S (M+H+); m/z, 2621.22; found, 2621.51. 
IPM-TP H2009.1: calculated for C105H171IN34O34S (M+H+); m/z, 2612.74; found, 
2613.49. 
IPM-Peptide29: calculated for C61H91IN20O22S3 (M+H+); m/z, 1679.60; found, 1680.29. 




The temporal changes in intact 125I-IFMDV2 in mouse serum are shown in 
Supplementary Table 1. The radiochemical purity of 125I-IFMDV2 was greater than 95% after a 
10-min incubation in serum and decreased gradually in a time-dependent manner. These data are 
in agreement with the data reported for other probes containing the A20FMDV2 sequence. 
 
 
Supplementary Table 1. Serum stability of 125I-IFMDV2 in vitro 
Incubation time (min) Intact form (%) 
10 95 ± 2 
60 67 ± 25 
120 50 ± 25 
Values are represented as the mean ± S.D. of 3 independent examinations. 
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High-performance liquid chromatography profiles of nonradioactive IFMDV2 (A) and 
125I-IFMDV2 (B). 125I-IFMDV2 showed a single peak at the retention time of 17.62 min that 
corresponded to the retention time of nonradioactive IFMDV2 (17.58 min). 
 
